25 XP   0   0   10

Kiniksa Pharmaceuticals Ltd
Buy, Hold or Sell?

Let's analyse Kiniksa together

PenkeI guess you are interested in Kiniksa Pharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kiniksa Pharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Kiniksa Pharmaceuticals Ltd

I send you an email if I find something interesting about Kiniksa Pharmaceuticals Ltd.

Quick analysis of Kiniksa (30 sec.)










What can you expect buying and holding a share of Kiniksa? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$6.04
Expected worth in 1 year
$6.53
How sure are you?
41.4%

+ What do you gain per year?

Total Gains per Share
$0.49
Return On Investment
2.8%

For what price can you sell your share?

Current Price per Share
$17.61
Expected price per share
$14.12 - $20.32
How sure are you?
50%

1. Valuation of Kiniksa (5 min.)




Live pricePrice per Share (EOD)

$17.61

Intrinsic Value Per Share

$26.23 - $31.88

Total Value Per Share

$32.27 - $37.92

2. Growth of Kiniksa (5 min.)




Is Kiniksa growing?

Current yearPrevious yearGrowGrow %
How rich?$438.8m$274.9m$136.4m33.2%

How much money is Kiniksa making?

Current yearPrevious yearGrowGrow %
Making money$3.5m$45.8m-$42.3m-1,201.9%
Net Profit Margin1.3%20.2%--

How much money comes from the company's main activities?

3. Financial Health of Kiniksa (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#130 / 1010

Most Revenue
#124 / 1010

Most Profit
#116 / 1010

Most Efficient
#153 / 1010

What can you expect buying and holding a share of Kiniksa? (5 min.)

Welcome investor! Kiniksa's management wants to use your money to grow the business. In return you get a share of Kiniksa.

What can you expect buying and holding a share of Kiniksa?

First you should know what it really means to hold a share of Kiniksa. And how you can make/lose money.

Speculation

The Price per Share of Kiniksa is $17.61. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kiniksa.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kiniksa, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.04. Based on the TTM, the Book Value Change Per Share is $0.12 per quarter. Based on the YOY, the Book Value Change Per Share is $0.72 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kiniksa.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.352.0%0.050.3%0.653.7%-0.26-1.5%-0.33-1.9%
Usd Book Value Change Per Share0.271.5%0.120.7%0.724.1%0.010.1%0.211.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.271.5%0.120.7%0.724.1%0.010.1%0.211.2%
Usd Price Per Share17.54-14.94-11.86-14.40-12.37-
Price to Earnings Ratio12.62--1.96-11.43--1.66--2.15-
Price-to-Total Gains Ratio65.59-273.08-14.02-54.09-45.21-
Price to Book Ratio2.90-2.57-3.39-3.38-2.70-
Price-to-Total Gains Ratio65.59-273.08-14.02-54.09-45.21-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share17.61
Number of shares56
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.120.01
Usd Total Gains Per Share0.120.01
Gains per Quarter (56 shares)6.840.77
Gains per Year (56 shares)27.383.10
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10271703-7
20554406-4
30827109-1
40110980122
501371250155
601641520198
7019217902211
8021920602514
9024623302817
10027426003120

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%4.08.00.033.3%4.016.00.020.0%5.024.00.017.2%5.024.00.017.2%
Book Value Change Per Share4.00.00.0100.0%6.06.00.050.0%9.011.00.045.0%12.014.03.041.4%12.014.03.041.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.029.00.0%0.00.029.00.0%
Total Gains per Share4.00.00.0100.0%6.06.00.050.0%9.011.00.045.0%12.014.03.041.4%12.014.03.041.4%

Fundamentals of Kiniksa

About Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Fundamental data was last updated by Penke on 2024-04-11 12:43:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Kiniksa Pharmaceuticals Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Kiniksa earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Kiniksa to the Biotechnology industry mean.
  • A Net Profit Margin of 30.3% means that $0.30 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kiniksa Pharmaceuticals Ltd:

  • The MRQ is 30.3%. The company is making a huge profit. +2
  • The TTM is 1.3%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ30.3%TTM1.3%+29.0%
TTM1.3%YOY20.2%-18.9%
TTM1.3%5Y-45.0%+46.3%
5Y-45.0%10Y-31.0%-14.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ30.3%-207.2%+237.5%
TTM1.3%-216.8%+218.1%
YOY20.2%-282.3%+302.5%
5Y-45.0%-436.8%+391.8%
10Y-31.0%-597.3%+566.3%
1.1.2. Return on Assets

Shows how efficient Kiniksa is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kiniksa to the Biotechnology industry mean.
  • 4.8% Return on Assets means that Kiniksa generated $0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kiniksa Pharmaceuticals Ltd:

  • The MRQ is 4.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 0.6%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ4.8%TTM0.6%+4.2%
TTM0.6%YOY7.3%-6.8%
TTM0.6%5Y-6.6%+7.2%
5Y-6.6%10Y-11.5%+4.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8%-13.3%+18.1%
TTM0.6%-12.8%+13.4%
YOY7.3%-11.6%+18.9%
5Y-6.6%-13.8%+7.2%
10Y-11.5%-15.6%+4.1%
1.1.3. Return on Equity

Shows how efficient Kiniksa is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kiniksa to the Biotechnology industry mean.
  • 5.8% Return on Equity means Kiniksa generated $0.06 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kiniksa Pharmaceuticals Ltd:

  • The MRQ is 5.8%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 1.4%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ5.8%TTM1.4%+4.3%
TTM1.4%YOY-+1.4%
TTM1.4%5Y-9.1%+10.5%
5Y-9.1%10Y-10.8%+1.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.8%-16.9%+22.7%
TTM1.4%-16.1%+17.5%
YOY--14.9%+14.9%
5Y-9.1%-19.3%+10.2%
10Y-10.8%-20.1%+9.3%

1.2. Operating Efficiency of Kiniksa Pharmaceuticals Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Kiniksa is operating .

  • Measures how much profit Kiniksa makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kiniksa to the Biotechnology industry mean.
  • An Operating Margin of 0.1% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kiniksa Pharmaceuticals Ltd:

  • The MRQ is 0.1%. The company is operating inefficient. -1
  • The TTM is -11.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ0.1%TTM-11.7%+11.8%
TTM-11.7%YOY-22.8%+11.1%
TTM-11.7%5Y-56.5%+44.8%
5Y-56.5%10Y-38.9%-17.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1%-298.0%+298.1%
TTM-11.7%-238.5%+226.8%
YOY-22.8%-288.4%+265.6%
5Y-56.5%-486.2%+429.7%
10Y-38.9%-628.4%+589.5%
1.2.2. Operating Ratio

Measures how efficient Kiniksa is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.00 means that the operating costs are $1.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Kiniksa Pharmaceuticals Ltd:

  • The MRQ is 0.999. The company is less efficient in keeping operating costs low.
  • The TTM is 1.109. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.999TTM1.109-0.110
TTM1.109YOY1.219-0.110
TTM1.1095Y1.102+0.007
5Y1.10210Y0.760+0.342
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9993.235-2.236
TTM1.1093.310-2.201
YOY1.2193.838-2.619
5Y1.1025.679-4.577
10Y0.7607.823-7.063

1.3. Liquidity of Kiniksa Pharmaceuticals Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Kiniksa is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.34 means the company has $4.34 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Kiniksa Pharmaceuticals Ltd:

  • The MRQ is 4.340. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.838. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.340TTM4.838-0.499
TTM4.838YOY4.381+0.457
TTM4.8385Y7.427-2.588
5Y7.42710Y7.674-0.247
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.3403.863+0.477
TTM4.8384.169+0.669
YOY4.3815.337-0.956
5Y7.4276.122+1.305
10Y7.6746.434+1.240
1.3.2. Quick Ratio

Measures if Kiniksa is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kiniksa to the Biotechnology industry mean.
  • A Quick Ratio of 5.12 means the company can pay off $5.12 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kiniksa Pharmaceuticals Ltd:

  • The MRQ is 5.121. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.172. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.121TTM6.172-1.050
TTM6.172YOY4.897+1.275
TTM6.1725Y10.737-4.565
5Y10.73710Y9.723+1.014
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.1213.504+1.617
TTM6.1723.991+2.181
YOY4.8975.371-0.474
5Y10.7376.088+4.649
10Y9.7236.395+3.328

1.4. Solvency of Kiniksa Pharmaceuticals Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Kiniksa assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kiniksa to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.17 means that Kiniksa assets are financed with 16.6% credit (debt) and the remaining percentage (100% - 16.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kiniksa Pharmaceuticals Ltd:

  • The MRQ is 0.166. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.149. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.166TTM0.149+0.017
TTM0.149YOY0.214-0.064
TTM0.1495Y0.144+0.005
5Y0.14410Y0.217-0.073
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1660.339-0.173
TTM0.1490.337-0.188
YOY0.2140.271-0.057
5Y0.1440.368-0.224
10Y0.2170.388-0.171
1.4.2. Debt to Equity Ratio

Measures if Kiniksa is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kiniksa to the Biotechnology industry mean.
  • A Debt to Equity ratio of 19.9% means that company has $0.20 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kiniksa Pharmaceuticals Ltd:

  • The MRQ is 0.199. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.050. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.199TTM0.050+0.150
TTM0.050YOY-+0.050
TTM0.0505Y0.092-0.042
5Y0.09210Y0.082+0.010
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1990.392-0.193
TTM0.0500.403-0.353
YOY-0.335-0.335
5Y0.0920.427-0.335
10Y0.0820.461-0.379

2. Market Valuation of Kiniksa Pharmaceuticals Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Kiniksa generates.

  • Above 15 is considered overpriced but always compare Kiniksa to the Biotechnology industry mean.
  • A PE ratio of 12.62 means the investor is paying $12.62 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kiniksa Pharmaceuticals Ltd:

  • The EOD is 12.675. Based on the earnings, the company is underpriced. +1
  • The MRQ is 12.625. Based on the earnings, the company is underpriced. +1
  • The TTM is -1.956. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD12.675MRQ12.625+0.050
MRQ12.625TTM-1.956+14.581
TTM-1.956YOY11.427-13.383
TTM-1.9565Y-1.656-0.300
5Y-1.65610Y-2.147+0.491
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD12.675-2.300+14.975
MRQ12.625-2.656+15.281
TTM-1.956-2.718+0.762
YOY11.427-4.145+15.572
5Y-1.656-6.258+4.602
10Y-2.147-6.315+4.168
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kiniksa Pharmaceuticals Ltd:

  • The EOD is 74.932. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 74.635. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is -4.473. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD74.932MRQ74.635+0.298
MRQ74.635TTM-4.473+79.108
TTM-4.473YOY-11.327+6.854
TTM-4.4735Y-7.192+2.719
5Y-7.19210Y-6.154-1.038
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD74.932-2.974+77.906
MRQ74.635-3.306+77.941
TTM-4.473-3.508-0.965
YOY-11.327-5.613-5.714
5Y-7.192-8.378+1.186
10Y-6.154-8.873+2.719
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Kiniksa is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.90 means the investor is paying $2.90 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Kiniksa Pharmaceuticals Ltd:

  • The EOD is 2.916. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.904. Based on the equity, the company is underpriced. +1
  • The TTM is 2.572. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.916MRQ2.904+0.012
MRQ2.904TTM2.572+0.332
TTM2.572YOY3.391-0.820
TTM2.5725Y3.380-0.808
5Y3.38010Y2.702+0.678
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.9161.914+1.002
MRQ2.9042.116+0.788
TTM2.5722.097+0.475
YOY3.3912.881+0.510
5Y3.3803.550-0.170
10Y2.7023.936-1.234
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Kiniksa Pharmaceuticals Ltd.

3.1. Institutions holding Kiniksa Pharmaceuticals Ltd

Institutions are holding 89.507% of the shares of Kiniksa Pharmaceuticals Ltd.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc4.50410.00143180588622801.9972
2023-12-31Vanguard Group Inc4.19920.0011296529963420.2143
2023-12-31Rubric Capital Management LP4.11741.05822907501-169948-5.5224
2023-12-31Fairmount Funds Management LLC4.0835.3433288322140866016.5144
2023-12-31Baker Bros Advisors LP3.97870.5607280957700
2023-12-31Goldman Sachs Group Inc2.57510.00291818424952642110.0325
2023-12-31Morgan Stanley - Brokerage Accounts2.25940.002515954791039906.9722
2023-12-31Pictet Asset Manangement SA2.22450.03041570816-33901-2.1126
2023-12-31State Street Corporation2.18950.00131546096-215576-12.237
2023-12-31Granahan Investment Management Inc..1.0230.418572238818817435.2245
2023-12-31ArrowMark Colorado Holdings, LLC (ArrowMark Partners)1.01240.1384714879-45474-5.9806
2023-12-31Geode Capital Management, LLC0.99070.0013699613400446.0712
2023-12-31Driehaus Capital Management LLC0.93710.139866171515796531.3578
2023-12-31Rice Hall James & Associates, LLC0.90070.646636029-14337-2.2045
2023-12-31Parkman Healthcare Partners LLC0.87191.521161569310588320.7691
2023-09-30TANG CAPITAL MANAGEMENT LLC0.84971.470660000000
2023-12-31Altitude Crest Partners Inc0.64585.35264560414560410
2023-12-31Millennium Management LLC0.60660.0033428335-177239-29.2679
2023-12-31Nuveen Asset Management, LLC0.58210.0023411024-152902-27.1138
2023-12-31Dimensional Fund Advisors, Inc.0.49530.0018349753-23968-6.4133
Total 39.046216.697527572471+1648676+6.0%

3.2. Funds holding Kiniksa Pharmaceuticals Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28SPDR® S&P Biotech ETF1.6620.30671173612148001.2772
2023-12-31Pictet-Biotech P USD1.37591.0789971608-75612-7.2203
2024-02-29Vanguard Total Stock Mkt Idx Inv1.26560.001289371300
2024-03-28iShares Russell 2000 ETF1.10550.0235780639141201.8421
2024-02-29Vanguard Small Cap Index1.09880.011777589172480.943
2024-02-29Vanguard Small Cap Value Index Inv0.75060.021153007122080.4183
2023-12-31Pictet-Global Megatrend Sel I USD0.69520.068649092313581538.2461
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.63510.00934484982290.0511
2024-01-31TIAA-CREF Quant Small-Cap Equity Instl0.46130.191832578000
2024-01-31Fidelity Small Cap Index0.45150.022731886020220.6382
2024-03-28iShares Russell 2000 Value ETF0.41950.0466296243-188-0.0634
2024-03-28iShares Biotechnology ETF0.41430.07562925343446313.3541
2024-02-29Heptagon Driehaus US Micro Cap Eq C$ Acc0.37520.688626497300
2023-12-31ArrowMark Small Cap Gro0.35340.6962249574-38682-13.4193
2023-12-31Meridian Small Cap Growth Legacy0.35340.693249574-38682-13.4193
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.27880.0119687135001.81
2024-02-29BlackRock Advantage Small Cap Core Instl0.27210.1157192153-11728-5.7524
2024-01-31Goldman Sachs Small Cp Val Insghts Instl0.26390.3783186335-42624-18.6164
2023-12-31M&G (ACS) Granahan US Sm Cp Gr GBPZ1AAcc0.26370.74951862465720.3081
2024-02-29Fidelity Extended Market Index0.25810.0118223871244.0682
Total 12.75395.1999006336+14585+0.2%

3.3. Insider Transactions

Insiders are holding 3.941% of the shares of Kiniksa Pharmaceuticals Ltd.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-06Sanj K PatelSELL558221
2024-03-04Sanj K PatelSELL1274221.49
2024-03-01Michael R MegnaSELL965921.45
2024-02-28Michael R MegnaSELL512621.79
2024-01-03Mark RagosaSELL1200020
2024-01-02Michael R MegnaSELL1667019.17
2023-12-19Michael R MegnaSELL931619.13
2023-12-07John F PaoliniSELL2860017.65
2023-09-05John F PaoliniSELL40017.53
2023-07-25John F PaoliniSELL2900019.14

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Kiniksa Pharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2670.122+119%0.717-63%0.014+1833%0.208+28%
Book Value Per Share--6.0405.788+4%3.903+55%4.486+35%4.076+48%
Current Ratio--4.3404.838-10%4.381-1%7.427-42%7.674-43%
Debt To Asset Ratio--0.1660.149+11%0.214-22%0.144+15%0.217-23%
Debt To Equity Ratio--0.1990.050+300%-+100%0.092+116%0.082+143%
Dividend Per Share----0%-0%-0%-0%
Eps--0.3470.046+659%0.646-46%-0.257+174%-0.331+195%
Free Cash Flow Per Share--0.0590.047+26%0.017+236%-0.356+706%-0.372+734%
Free Cash Flow To Equity Per Share--0.0680.052+32%0.026+159%-0.087+227%0.522-87%
Gross Profit Margin--1.0001.0000%1.0000%1.0040%1.0020%
Intrinsic Value_10Y_max--31.879--------
Intrinsic Value_10Y_min--26.227--------
Intrinsic Value_1Y_max---0.076--------
Intrinsic Value_1Y_min---0.076--------
Intrinsic Value_3Y_max--2.265--------
Intrinsic Value_3Y_min--2.112--------
Intrinsic Value_5Y_max--7.610--------
Intrinsic Value_5Y_min--6.849--------
Market Cap704053083.000-81%1274459399.3401063183935.325+20%833410514.465+53%934393212.824+36%757634829.302+68%
Net Profit Margin--0.3030.013+2244%0.202+50%-0.450+249%-0.310+203%
Operating Margin--0.001-0.117+12132%-0.228+23609%-0.565+58225%-0.389+40186%
Operating Ratio--0.9991.109-10%1.219-18%1.102-9%0.760+31%
Pb Ratio2.916+0%2.9042.572+13%3.391-14%3.380-14%2.702+7%
Pe Ratio12.675+0%12.625-1.956+115%11.427+10%-1.656+113%-2.147+117%
Price Per Share17.610+0%17.54014.938+17%11.863+48%14.396+22%12.374+42%
Price To Free Cash Flow Ratio74.932+0%74.635-4.473+106%-11.327+115%-7.192+110%-6.154+108%
Price To Total Gains Ratio65.852+0%65.590273.084-76%14.016+368%54.089+21%45.213+45%
Quick Ratio--5.1216.172-17%4.897+5%10.737-52%9.723-47%
Return On Assets--0.0480.006+753%0.073-35%-0.066+238%-0.115+340%
Return On Equity--0.0580.014+300%-+100%-0.091+257%-0.108+287%
Total Gains Per Share--0.2670.122+119%0.717-63%0.014+1833%0.208+28%
Usd Book Value--438839000.000411429250.000+7%274973750.000+60%291846100.000+50%245149310.345+79%
Usd Book Value Change Per Share--0.2670.122+119%0.717-63%0.014+1833%0.208+28%
Usd Book Value Per Share--6.0405.788+4%3.903+55%4.486+35%4.076+48%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.3470.046+659%0.646-46%-0.257+174%-0.331+195%
Usd Free Cash Flow--4269000.0003292750.000+30%1425500.000+199%-21311350.000+599%-20161620.690+572%
Usd Free Cash Flow Per Share--0.0590.047+26%0.017+236%-0.356+706%-0.372+734%
Usd Free Cash Flow To Equity Per Share--0.0680.052+32%0.026+159%-0.087+227%0.522-87%
Usd Market Cap704053083.000-81%1274459399.3401063183935.325+20%833410514.465+53%934393212.824+36%757634829.302+68%
Usd Price Per Share17.610+0%17.54014.938+17%11.863+48%14.396+22%12.374+42%
Usd Profit--25237000.0003521000.000+617%45840750.000-45%-14186250.000+156%-16406862.069+165%
Usd Revenue--83395000.00067564750.000+23%55045000.000+52%26449150.000+215%18240793.103+357%
Usd Total Gains Per Share--0.2670.122+119%0.717-63%0.014+1833%0.208+28%
 EOD+2 -6MRQTTM+24 -9YOY+20 -135Y+26 -810Y+23 -11

4.2. Fundamental Score

Let's check the fundamental score of Kiniksa Pharmaceuticals Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1512.675
Price to Book Ratio (EOD)Between0-12.916
Net Profit Margin (MRQ)Greater than00.303
Operating Margin (MRQ)Greater than00.001
Quick Ratio (MRQ)Greater than15.121
Current Ratio (MRQ)Greater than14.340
Debt to Asset Ratio (MRQ)Less than10.166
Debt to Equity Ratio (MRQ)Less than10.199
Return on Equity (MRQ)Greater than0.150.058
Return on Assets (MRQ)Greater than0.050.048
Total7/10 (70.0%)

4.3. Technical Score

Let's check the technical score of Kiniksa Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.744
Ma 20Greater thanMa 5017.805
Ma 50Greater thanMa 10019.275
Ma 100Greater thanMa 20018.825
OpenGreater thanClose17.710
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Total Stockholder Equity -492,034-12,270-504,30414,972-489,332-13,855-503,187942,026438,839
Other Stockholders Equity  -63-6-6942-2713-14916,777916,763
Liabilities and Stockholders Equity  -428,511-23,026-451,53734,881-416,656-8,595-425,251951,573526,322



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets526,322
Total Liabilities87,483
Total Stockholder Equity438,839
 As reported
Total Liabilities 87,483
Total Stockholder Equity+ 438,839
Total Assets = 526,322

Assets

Total Assets526,322
Total Current Assets276,297
Long-term Assets250,025
Total Current Assets
Cash And Cash Equivalents 107,954
Short-term Investments 98,417
Net Receivables 21,266
Inventory 31,122
Other Current Assets 17,538
Total Current Assets  (as reported)276,297
Total Current Assets  (calculated)276,297
+/-0
Long-term Assets
Property Plant Equipment 12,665
Intangible Assets 17,250
Long-term Assets Other 827
Long-term Assets  (as reported)250,025
Long-term Assets  (calculated)30,742
+/- 219,283

Liabilities & Shareholders' Equity

Total Current Liabilities63,666
Long-term Liabilities23,817
Total Stockholder Equity438,839
Total Current Liabilities
Short-term Debt 2,253
Accounts payable 8,246
Other Current Liabilities 52,860
Total Current Liabilities  (as reported)63,666
Total Current Liabilities  (calculated)63,359
+/- 307
Long-term Liabilities
Capital Lease Obligations 12,258
Long-term Liabilities Other 1,858
Long-term Liabilities  (as reported)23,817
Long-term Liabilities  (calculated)14,116
+/- 9,701
Total Stockholder Equity
Common Stock20
Retained Earnings -477,950
Accumulated Other Comprehensive Income 6
Other Stockholders Equity 916,763
Total Stockholder Equity (as reported)438,839
Total Stockholder Equity (calculated)438,839
+/-0
Other
Capital Stock20
Cash and Short Term Investments 206,371
Common Stock Shares Outstanding 72,660
Current Deferred Revenue307
Liabilities and Stockholders Equity 526,322
Net Debt -95,696
Net Invested Capital 438,839
Net Working Capital 212,631
Property Plant and Equipment Gross 20,450
Short Long Term Debt Total 12,258



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
56,467
0
0
0
47,492
224,775
365,129
347,101
321,965
346,159
308,137
281,805
254,534
226,108
271,441
384,413
349,464
311,158
279,208
252,859
232,800
230,965
210,576
459,953
459,672
442,862
484,332
483,063
526,322
526,322483,063484,332442,862459,672459,953210,576230,965232,800252,859279,208311,158349,464384,413271,441226,108254,534281,805308,137346,159321,965347,101365,129224,77547,49200056,467
   > Total Current Assets 
56,334
0
0
0
47,104
222,453
363,869
341,528
313,750
334,956
296,458
268,340
241,627
213,055
264,493
378,413
333,249
275,564
244,810
217,512
196,446
198,757
179,938
241,815
243,060
231,500
184,992
256,109
276,297
276,297256,109184,992231,500243,060241,815179,938198,757196,446217,512244,810275,564333,249378,413264,493213,055241,627268,340296,458334,956313,750341,528363,869222,45347,10400056,334
       Cash And Cash Equivalents 
55,970
0
0
0
45,555
221,108
285,518
337,863
307,304
326,533
287,447
258,745
46,928
106,336
123,456
85,874
114,038
119,856
167,953
190,183
122,470
63,324
94,307
175,761
122,715
80,618
112,567
117,828
107,954
107,954117,828112,56780,618122,715175,76194,30763,324122,470190,183167,953119,856114,03885,874123,456106,33646,928258,745287,447326,533307,304337,863285,518221,10845,55500055,970
       Short-term Investments 
105
0
0
0
105
105
73,672
268,200
235,328
243,904
204,637
189,936
186,452
97,870
128,942
278,521
209,444
144,169
57,913
10,000
59,731
82,253
43,901
24,963
67,893
106,876
72,425
83,256
98,417
98,41783,25672,425106,87667,89324,96343,90182,25359,73110,00057,913144,169209,444278,521128,94297,870186,452189,936204,637243,904235,328268,20073,672105105000105
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
210
2,551
3,224
3,985
29,440
7,808
11,159
20,316
7,424
24,650
3,041
21,266
21,2663,04124,6507,42420,31611,1597,80829,4403,9853,2242,55121000000000000000000
       Other Current Assets 
259
0
0
0
1,444
1,240
4,416
3,665
6,446
8,423
9,011
9,595
8,247
8,849
12,095
14,018
9,557
9,140
9,802
8,499
6,585
10,517
14,006
15,311
10,537
150,882
12,440
26,401
17,538
17,53826,40112,440150,88210,53715,31114,00610,5176,5858,4999,8029,1409,55714,01812,0958,8498,2479,5959,0118,4236,4463,6654,4161,2401,444000259
   > Long-term Assets 
0
0
0
0
388
2,322
1,260
5,573
8,215
11,203
11,679
13,465
12,907
13,053
6,948
6,000
16,215
35,594
34,398
35,347
36,354
32,208
30,638
218,138
216,612
211,362
238,292
226,954
250,025
250,025226,954238,292211,362216,612218,13830,63832,20836,35435,34734,39835,59416,2156,0006,94813,05312,90713,46511,67911,2038,2155,5731,2602,3223880000
       Property Plant Equipment 
84
0
0
0
125
126
350
2,360
6,356
9,537
8,862
8,627
8,325
7,433
6,533
5,739
10,617
9,797
8,835
9,296
8,384
7,290
6,219
8,168
7,043
1,393
14,327
13,586
12,665
12,66513,58614,3271,3937,0438,1686,2197,2908,3849,2968,8359,79710,6175,7396,5337,4338,3258,6278,8629,5376,3562,36035012612500084
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20,000
19,750
19,500
19,250
19,000
18,750
18,500
18,250
18,000
17,750
17,500
17,250
17,25017,50017,75018,00018,25018,50018,75019,00019,25019,50019,75020,00000000000000000000
       Long-term Assets Other 
0
0
0
0
25
1,818
210
2,040
643
210
210
210
210
210
415
258
5,588
5,797
5,813
6,551
8,720
5,918
5,669
5,627
5,824
7,551
2,353
2,294
827
8272,2942,3537,5515,8245,6275,6695,9188,7206,5515,8135,7975,5882584152102102102102106432,0402101,818250000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
700
1,173
1,649
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,6491,173700000000
> Total Liabilities 
2,302
0
0
0
137,200
19,298
23,330
28,188
42,698
39,640
32,940
29,894
29,111
20,274
21,025
25,904
37,529
40,462
43,423
38,811
47,763
64,721
57,082
75,945
63,523
52,767
72,676
77,936
87,483
87,48377,93672,67652,76763,52375,94557,08264,72147,76338,81143,42340,46237,52925,90421,02520,27429,11129,89432,94039,64042,69828,18823,33019,298137,2000002,302
   > Total Current Liabilities 
2,302
0
0
0
17,430
19,268
23,144
28,021
42,554
36,892
30,178
27,560
27,830
19,342
20,552
24,892
31,846
35,453
38,782
34,427
44,824
50,354
43,544
56,492
47,066
36,587
47,472
53,468
63,666
63,66653,46847,47236,58747,06656,49243,54450,35444,82434,42738,78235,45331,84624,89220,55219,34227,83027,56030,17836,89242,55428,02123,14419,26817,4300002,302
       Short-term Debt 
0
0
0
0
0
0
0
0
0
1,384
1,496
1,610
1,697
1,689
1,680
1,492
2,107
2,374
2,636
3,246
3,381
3,311
3,336
3,274
3,301
3,482
2,238
2,313
2,253
2,2532,3132,2383,4823,3013,2743,3363,3113,3813,2462,6362,3742,1071,4921,6801,6891,6971,6101,4961,384000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
1,384
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001,384000000000
       Accounts payable 
212
0
0
0
1,218
2,796
561
4,668
10,918
6,890
9,338
6,440
5,693
4,274
2,373
3,925
503
2,763
4,156
1,649
1,868
3,383
2,522
1,469
7,899
1,391
648
1,012
8,246
8,2461,0126481,3917,8991,4692,5223,3831,8681,6494,1562,7635033,9252,3734,2745,6936,4409,3386,89010,9184,6685612,7961,218000212
       Other Current Liabilities 
2,090
0
0
0
16,212
16,472
22,583
23,353
31,636
1,384
165
19,510
25
13,379
16,499
19,475
37
30,316
926
1,004
1,544
31,660
25,686
39,657
23,866
25,219
39,912
47,579
52,860
52,86047,57939,91225,21923,86639,65725,68631,6601,5441,00492630,3163719,47516,49913,3792519,5101651,38431,63623,35322,58316,47216,2120002,090
   > Long-term Liabilities 
0
0
0
0
119,770
30
186
167
144
2,748
2,762
2,334
1,281
932
473
1,012
5,683
5,009
4,641
4,384
2,939
14,367
13,538
19,453
16,457
16,180
25,204
24,468
23,817
23,81724,46825,20416,18016,45719,45313,53814,3672,9394,3844,6415,0095,6831,0124739321,2812,3342,7622,74814416718630119,7700000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
2,239
1,819
1,391
955
551
139
55
4,878
4,200
3,500
3,499
2,669
2,096
1,278
3,435
2,618
2,133
11,283
10,651
10,005
10,00510,65111,2832,1332,6183,4351,2782,0962,6693,4993,5004,2004,878551395519551,3911,8192,239000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
700
1,173
1,649
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,6491,173700000000
       Other Liabilities 
0
0
0
0
0
30
186
167
144
509
943
943
326
381
334
957
805
809
1,141
885
270
12,271
12,260
16,018
13,839
0
13,921
13,817
0
013,81713,921013,83916,01812,26012,2712708851,1418098059573343813269439435091441671863000000
> Total Stockholder Equity
54,165
-25,732
0
0
-89,708
205,477
341,799
318,913
279,267
306,519
275,197
251,911
225,423
205,834
250,416
358,509
311,935
270,696
235,785
214,048
185,037
-700,607
-720,588
-496,495
-492,034
-504,304
-489,332
-503,187
438,839
438,839-503,187-489,332-504,304-492,034-496,495-720,588-700,607185,037214,048235,785270,696311,935358,509250,416205,834225,423251,911275,197306,519279,267318,913341,799205,477-89,70800-25,73254,165
   Common Stock
1
0
0
0
1
11
13
13
13
15
15
15
15
15
16
18
18
18
18
18
18
19
19
19
19
14
14
15
20
20151414191919191818181818181615151515151313131110001
   Retained Earnings Total Equity00-489,332-504,304-492,034-496,495-720,588-700,607-675,397-639,064-608,520-566,957-517,473-463,8160-382,511-356,092-324,295-297,237-260,046-194,225-151,645-127,239000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-52
-42
7
-55
-4
8
101
62
33
240
9
6
-34
-21
27
-45
-66
-103
-90
-70
44
55
13
-1
6
6-1135544-70-90-103-66-4527-21-346924033621018-4-557-42-520000
   Capital Surplus 
0
0
0
0
0
0
469,018
470,600
473,483
566,542
572,318
576,129
581,467
588,090
0
822,301
829,424
837,656
844,260
853,139
860,482
866,935
874,153
880,554
888,120
894,325
900,956
0
0
00900,956894,325888,120880,554874,153866,935860,482853,139844,260837,656829,424822,3010588,090581,467576,129572,318566,542473,483470,600469,018000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
1,341
312,488
469,018
470,600
473,483
566,542
572,318
576,129
581,467
588,090
670,371
822,301
829,424
837,656
844,260
853,139
860,482
84
71
51
-63
-69
-27
-14
916,763
916,763-14-27-69-63517184860,482853,139844,260837,656829,424822,301670,371588,090581,467576,129572,318566,542473,483470,600469,018312,4881,3410000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue270,259
Cost of Revenue-91,040
Gross Profit179,219179,219
 
Operating Income (+$)
Gross Profit179,219
Operating Expense-204,415
Operating Income-25,196-25,196
 
Operating Expense (+$)
Research Development74,988
Selling General Administrative119,903
Selling And Marketing Expenses0
Operating Expense204,415194,891
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-25,196
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-16,652-33,740
EBIT - interestExpense = -25,196
-16,652
14,084
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-25,196-16,652
Earnings Before Interest and Taxes (EBITDA)-23,087
 
After tax Income (+$)
Income Before Tax-16,652
Tax Provision--5,569
Net Income From Continuing Ops-6,692-11,083
Net Income14,084
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses295,455
Total Other Income/Expenses Net8,5440
 

Technical Analysis of Kiniksa
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kiniksa. The general trend of Kiniksa is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kiniksa's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kiniksa Pharmaceuticals Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 19.15 < 19.20 < 20.32.

The bearish price targets are: 16.82 > 14.17 > 14.12.

Tweet this
Kiniksa Pharmaceuticals Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kiniksa Pharmaceuticals Ltd. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kiniksa Pharmaceuticals Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kiniksa Pharmaceuticals Ltd. The current macd is -0.53960781.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Kiniksa price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Kiniksa. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Kiniksa price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Kiniksa Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) ChartKiniksa Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kiniksa Pharmaceuticals Ltd. The current adx is 26.03.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Kiniksa shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Kiniksa Pharmaceuticals Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kiniksa Pharmaceuticals Ltd. The current sar is 16.74.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Kiniksa Pharmaceuticals Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kiniksa Pharmaceuticals Ltd. The current rsi is 41.74. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Kiniksa Pharmaceuticals Ltd Daily Relative Strength Index (RSI) ChartKiniksa Pharmaceuticals Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kiniksa Pharmaceuticals Ltd. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kiniksa price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Kiniksa Pharmaceuticals Ltd Daily Stochastic Oscillator ChartKiniksa Pharmaceuticals Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kiniksa Pharmaceuticals Ltd. The current cci is -10.98475036.

Kiniksa Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) ChartKiniksa Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kiniksa Pharmaceuticals Ltd. The current cmo is -8.45639051.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Kiniksa Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) ChartKiniksa Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kiniksa Pharmaceuticals Ltd. The current willr is -48.7804878.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Kiniksa is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Kiniksa Pharmaceuticals Ltd Daily Williams %R ChartKiniksa Pharmaceuticals Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kiniksa Pharmaceuticals Ltd. The current atr is 0.63449775.

Kiniksa Pharmaceuticals Ltd Daily Average True Range (ATR) ChartKiniksa Pharmaceuticals Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kiniksa Pharmaceuticals Ltd. The current obv is 19,268,745.

Kiniksa Pharmaceuticals Ltd Daily On-Balance Volume (OBV) ChartKiniksa Pharmaceuticals Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kiniksa Pharmaceuticals Ltd. The current mfi is 50.91.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Kiniksa Pharmaceuticals Ltd Daily Money Flow Index (MFI) ChartKiniksa Pharmaceuticals Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kiniksa Pharmaceuticals Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Kiniksa Pharmaceuticals Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kiniksa Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.744
Ma 20Greater thanMa 5017.805
Ma 50Greater thanMa 10019.275
Ma 100Greater thanMa 20018.825
OpenGreater thanClose17.710
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Kiniksa with someone you think should read this too:
  • Are you bullish or bearish on Kiniksa? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kiniksa? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kiniksa Pharmaceuticals Ltd

I send you an email if I find something interesting about Kiniksa Pharmaceuticals Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Kiniksa Pharmaceuticals Ltd.

Receive notifications about Kiniksa Pharmaceuticals Ltd in your mailbox!